The Occurrence of Abdominal Aortic Aneurysms in Patients With Ruptured Intracranial Aneurysms
The Occurrence of Abdominal Aortic Aneurysms in Patients With Ruptured Intracranial Aneurysms
Rationale: Aneurysms of different types are known to be associated. In literature, concurrence of intracranial- and aortic aneurysms is described. Screening for aortic aneurysms (AA) in patients with intracranial aneurysms (IA) or aneurysmal subarachnoid haemorrhage (aSAH) could be cost-effective and of significant importance to decrease morbidity and mortality. The available literature on the association between the two types of aneurysms is sparse and in general of poor methodological quality. This protocol presents a study to more adequately evaluate the association between IA and AA.
Objective: To investigate the occurrence of abdominal aortic aneurysms (AAA) in patients who experienced aSAH.
Study design: This single cohort prospective study will include patients who experienced aSAH. The study participants will receive an abdominal ultrasound of the aorta to detect an AAA.
Study population: aSAH patients from a prospective cohort trial in the Netherlands.
Main study parameters/endpoints: The primary outcome, which will be investigated in the here above described study population, is the number of AAA detected on abdominal ultrasound.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will not receive an intervention, but only a diagnostic imaging without radiation. The burden associated with this study are considered minimal and the risks negligible. An abdominal ultrasound is a non-invasive diagnostic method with no risks for the participant. The only possible existing burden to the participant is travel and appointment time with a risk of detecting an abdominal aortic aneurysm or other (occult) intra-abdominal pathologies. When an aneurysm, sub-aneurysm or other intra-abdominal pathology is detected, surveillance or treatment according to standard of care and guidelines will follow.
This study will be a prospective single cohort study.
During the period of the study, all aSAH patients (from another prospective cohort trial) will be screened for inclusion eligibility. Eligible patients will be included as subjects in this study. Study subjects will receive an abdominal ultrasound (US) focused on the aorta. Detecting an AAA on abdominal US will result in the daily standard of care for AAA, including surveillance and possible treatment by medication, intervention or surgery.
Study sites This study will be conducted by the Department of Surgery in the main study location University Medical Center Leiden (LUMC) in collaboration with University Neurosurgical Center Holland (UNCH). Eligibility screening and inclusion will be performed by the LUMC.
To answer the research questions of this study, the US laboratory of the LUMC will perform US on the included patients.
The clinical (neurovascular) centers who included patients in the SPARTA trial are:
The data from the aortic-scan centers will be obtained and centralized analysis will be performed by the main study location LUMC.
Number of study subjects The investigators will include 233 subjects as one single cohort. In this study, the collected data and analysis will be compared to the general- and at-risk population.
Study duration During an initial period of 2 months, patients will be included as study subjects. Inclusion stops when the targeted number of study subjects (N=233) is reached. The study duration is expected to be around 1.5 years and the study period will end when all 233 study subjects had an abdominal US, or were excluded from the study during the study period for particular reasons.
Inclusion Criteria:
In order to be eligible to participate in this study, a participant must meet all of the following criteria:
By being a study subject of the SPARTA trial, the following criteria are applicable:
Exclusion Criteria:
A potential participant who meets any of the following criteria will be excluded from participation in this study:
a.hamming@haaglandenmc.nl+31655322609